Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM4003 (Porustobart) Monotherapy in Advanced Solid Tumors
NCT04135261Phase 1Completed
- Sponsor
- Harbour BioMed
- Start
- Sep 2019
- Primary completion
- Jan 2023
- Modality
- Antibody Conjugates, Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of porustobart in solid tumor (advanced stage), melanoma, hepatocellular carcinoma (HCC) and 1 more (2 arms), sponsored by Harbour BioMed. Primary endpoints: Dose-Limiting Toxicity and Objective Response Rate. Started Sep 2019; status: completed.
02
Drugs
porustobart
03
Conditions
solid tumor (advanced stage)melanomahepatocellular carcinoma (HCC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04135261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04135261.